DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valcyte (Valganciclovir Hydrochloride) - Published Studies

 
 



Valcyte Related Published Studies

Well-designed clinical trials related to Valcyte (Valganciclovir)

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. [2011.09]

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. [2011.05.15]

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. [2010.12.27]

Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. [2010.12.27]

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. [2010.08.27]

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. [2010.06.15]

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. [2010.05]

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. [2010]

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. [2009.05]

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. [2009]

Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. [2008.07.01]

Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. [2008.01]

Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. [2006.06]

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. [2006.04.01]

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. [2005.06.15]

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. [2005]

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. [2004.05.01]

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. [2004.04]

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. [2002.04.11]

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. [2001.12.15]

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. [2000.10]

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. [1999.08]

Well-designed clinical trials possibly related to Valcyte (Valganciclovir)

Cytomegalovirus. [2014]

Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients. [2011.08]

Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). [2011.05]

Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. [2010.08]

Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. [2010]

Antiviral agents for treatment of herpes simplex virus infection in neonates. [2009.07.08]

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. [2009.05]

Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. [2009.05]

An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. [2009.02]

Cytomegalovirus infection after liver transplantation: current concepts and challenges. [2008.08.21]

Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. [2007.05]

Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. [2006.07.27]

A surveillance study of adenovirus infection in adult solid organ transplant recipients. [2005.10]

Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. [2005.09]

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. [2005.05]

Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. [2004.12.27]

Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. [2004.04]

Other research related to Valcyte (Valganciclovir)

Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. [2013]

[The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]. [Article in Polish] [2013]

Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. [2012]

Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. [2012]

Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. [2012]

Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial. [2011.11.16]

Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. [2011.11]

Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. [2011.10.28]

Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: A randomized trial. [2011.10]

Successful corneal autograft after clearance of anterior chamber cytomegalovirus with oral valganciclovir in a patient with multiple failed corneal allografts. [2011.09]

Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. [2011.07]

High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. [2011.06.30]

Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. [2011.04.15]

Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. [2011.03]

Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. [2011.02.01]

Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. [2011.01.27]

24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. [2011.01.27]

Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. [2011.01]

Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial. [2011]

Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. [2011]

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. [2011]

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. [2010.12]

Viral-associated trichodysplasia of immunosuppression: report of a pediatric patient with response to oral valganciclovir. [2010.08]

Valganciclovir: recent progress. [2010.06]

Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. [2010.06]

Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. [2010.06]

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. [2010.05]

Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. [2010.04]

Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis. [2010.02]

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. [2010.01.06]

High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. [2010]

Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. [2010]

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. [2010]

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. [2010]

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. [2010]

Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. [2009.12]

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. [2009.11]

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. [2009.08]

Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. [2009.07]

Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. [2009.06]

Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. [2009.06]

[Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection] [2009.06]

A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. [2009.05]

Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. [2009.04]

Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. [2009.04]

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. [2009.04]

Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. [2009.03]

Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. [2009.03]

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. [2009.03]

Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. [2009.03]

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]

Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. [2009.02]

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. [2009.01]

Human herpesvirus 6 meningoradiculitis treated with intravenous immunoglobulin and valganciclovir. [2009.01]

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. [2009]

Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. [2009]

Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. [2009]

[Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation] [2008.12.16]

Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. [2008.11]

Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. [2008.10]

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2008.09.19]

Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. [2008.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017